Everything below concerns TB-500. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
As of 2014, it has 450 employees working at 3 locations, including distribution centers in North Las Vegas, NV; Shiremanstown, PA; and Bedfordshire, U.K. The corporate headquarters is also located in Boise, along with the company's customer service call center. In 2013, the company donated the equipment for Boise's first outdoor gym, located in Ann Morrison Park. In September 2015, Ryan Deluca suddenly announced he would be stepping down from his position as CEO. In November, Liberty Interactive spun off Bodybuilding.com and its stake in Expedia into a new company, Liberty Expedia Holdings. After Bodybuilding.com laid off 90 people in December 2016, it reorganized to form 4 different companies/brands. In February 2019, hackers accessed some part of Bodybuilding.com's corporate IT systems, and may have retrieved personal data of the site's users. Sometime in the next few months, the company discovered this, but did not publicize it right away, instead hiring a security company to assess what their vulnerability had been. It was found that at least one of Bodybuilding.com's 450 employees had been susceptible to a phishing email sent in July 2018. It was not determined if the hackers accessed user data. In April 2019, Bodybuilding.com publicized the breach, saying its consequences were unknown, and reset all the passwords of the site's users.
As a result of tight advertising and marketing prohibitions, tobacco companies view packaging as a vital factor in displaying brand imagery and creating in-store presence at the point of purchase. Market testing shows the influence of this dimension in shifting the consumer's choice when the same product is displayed in alternative packaging. Companies have manipulated a variety of elements on packaging designs to communicate the impression of lower tar content or milder cigarettes, although the actual contents were the same. Some countries require cigarette packs to display warnings about the health impact of smoking. The United States was the first, later followed by other countries including Canada, most of Europe, the United Kingdom, Australia, Pakistan, India and Hong Kong. In 1985, Iceland became the first country to enforce graphic warnings on cigarette packaging. At the end of December 2010, new regulations in Canada increased the size of tobacco warnings to cover three-quarters of cigarette packaging. As of November 2010, 39 countries have adopted similar legislation. In February 2011, the Canadian government passed regulations requiring cigarette packaging to contain 12 new images to cover three quarters of the outside panel and eight new health messages on the inside panel with full color. As of April 2011, Australian regulations require all packaging to use a bland olive green that researchers determined to be the least attractive color, with 75% coverage on the front of the pack and all of the back consisting of graphic health warnings.
An even older naming system for metal cations, also still widely used, appended the suffixes -ous and -ic to the Latin root of the name, to give special names for the low and high oxidation states. For example, this scheme uses "ferrous" and "ferric", for iron(II) and iron(III) respectively, so the examples given above were classically named ferrous sulfate and ferric sulfate. Common salt-forming cations include:
== Further reading == Law, Kate (2017). "Pattern, Puzzle, and Peculiarity: Rhodesia's UDI and Decolonisation in Southern Africa". The Journal of Imperial and Commonwealth History. 45 (5): 721–728. doi:10.1080/03086534.2017.1370219. S2CID 159738781. Michel, Eddie (2019). The White House and White Africa: Presidential Policy Toward Rhodesia During the UDI Era, 1965-1979. New York: Routledge. ISBN 978-1138319998. Mitchell, Nancy (2016). Jimmy Carter in Africa: Race and the Cold War. Stanford, California: Stanford University Press. ISBN 978-0804793858. Mlombo, Abraham (2020). Southern Rhodesia–South Africa Relations, 1923–1953. doi:10.1007/978-3-030-54283-2. ISBN 978-3-030-54282-5. S2CID 226514581. Nyamunda, Tinashe (2016). "'More a Cause than a Country': Historiography, UDI and the Crisis of Decolonisation in Rhodesia". Journal of Southern African Studies. 42 (5): 1005–1019. doi:10.1080/03057070.2016.1222796. S2CID 152098914. Nyamunda, Tinashe (2020). "Money, Banking and Rhodesia's Unilateral Declaration of Independence". The Decolonisation of Zimbabwe. pp. 26–56. doi:10.4324/9780429020179-3. ISBN 9780429020179. S2CID 242256859. Waddy, Nicholas (2014). "The Strange Death of 'Zimbabwe-Rhodesia': The Question of British Recognition of the Muzorewa Regime in Rhodesian Public Opinion, 1979". South African Historical Journal. 66 (2): 227–248. doi:10.1080/02582473.2013.846935. S2CID 159650816. Waddy, Nicholas L. (2017). "Free and Fair? Rhodesians Reflect on the Elections of 1979 and 1980". African Historical Review. 49: 68–90. doi:10.1080/17532523.2017.1357323. S2CID 159934527.
Sources: en.wikipedia.org
== Immuno-based analysers == Antibodies are used by some analysers to detect many substances by immunoassay and other reactions that employ the use of antibody-antigen reactions. When concentration of these compounds is too low to cause a measurable increase in turbidity when bound to antibody, more specialised methods must be used. Recent developments include automation for the immunohaematology lab, also known as transfusion medicine.
Brewing has taken place since at least the 11th millennium BC, and archaeological evidence suggests that prehistoric peoples and later civilisations, including those in China, ancient Egypt, and Mesopotamia brewed beer. Descriptions of beer production can be found in cuneiform (the oldest known writing) from ancient Mesopotamia. In Mesopotamia the brewer's craft derived social sanction and divine protection from female deities/goddesses, specifically: Ninkasi, who covered the production of beer, Siris, who was used in a metonymic way to refer to beer, and Siduri, who appears in the Epic of Gilgamesh as a divine alewife or tavern-keeper, covered the enjoyment of beer. In pre-industrial times, and in developing countries, women are frequently the main brewers. As almost any cereal containing certain sugars can undergo spontaneous fermentation due to wild yeasts in the air and on the grains, it is possible that beer-like beverages were independently developed throughout the world in prehistoric times. The earliest archaeological evidence for cereal-based beer brewing has been found at Raqefet Cave in present-day Israel, where analysis of stone mortars indicates that the Natufians, a semi-sedentary foraging people, brewed wheat- or barley-based beer around 13,000 years ago, probably for ritual feasts. The brewing of beer at Raqefet Cave predates the appearance of domesticated cereals in the Near East by several millennia.
=== Definition === Aves and a sister group, the order Crocodilia, contain the only living representatives of the reptile clade Archosauria. During the late 1990s, Aves was most commonly defined phylogenetically as all descendants of the most recent common ancestor of modern birds and Archaeopteryx lithographica. However, an earlier definition proposed by Jacques Gauthier gained wide currency in the 21st century, and is used by many scientists including adherents to the PhyloCode. Gauthier defined Aves to include only the crown group of the set of modern birds. This was done by excluding most groups known only from fossils, and assigning them, instead, to the broader group Avialae, on the principle that a clade based on extant species should be limited to those extant species and their closest extinct relatives. Gauthier and de Queiroz identified four different definitions for the same biological name "Aves", which is a problem. The authors proposed to reserve the term Aves only for the crown group consisting of the last common ancestor of all living birds and all of its descendants, which corresponds to meaning number 4 below. They assigned other names to the other groups.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.